"RIV/00216208:11140/14:10272223" . "Sk\u00E1lov\u00E1, Alena" . "HER2/neu immunohistochmeistry; HER2/neu amplification; Herceptin therapy; HER2/neu testing; breast cancer"@en . "3"^^ . . . "30325" . . "RIV/00216208:11140/14:10272223!RIV15-MSM-11140___" . "Molekul\u00E1rn\u00ED testov\u00E1n\u00ED HEr2 u karcinomu prsu jako krit\u00E9rium v\u00FDb\u011Bru nemocn\u00FDch k l\u00E9\u010Db\u011B Herceptinem - jsme optim\u00E1ln\u00ED?" . "11140" . "1804-8218" . . . . . "[D1EFCA38B108]" . . "Molekul\u00E1rn\u00ED testov\u00E1n\u00ED HEr2 u karcinomu prsu jako krit\u00E9rium v\u00FDb\u011Bru nemocn\u00FDch k l\u00E9\u010Db\u011B Herceptinem - jsme optim\u00E1ln\u00ED?"@cs . "Kinkor, Zden\u011Bk" . "4" . "I" . "V souboru 2145 vy\u0161et\u0159ovan\u00FDch invazivn\u00EDch karcinom\u016F jsme prok\u00E1zali overexpresi HER2 (IHC2-3+) u 591 (27,6%) p\u0159\u00EDpad\u016F; celkem bylo 1554 (72,4%) negativn\u00EDch (IHC0/1+). P\u0159ekvapiv\u00FDm zji\u0161t\u011Bn\u00EDm byla p\u0159\u00EDtomnost amplifikace u 16 (1,03%) IHC negativn\u00EDch karcinom\u016F. Vzhledem k tomu, \u017Ee dodnes neexistuje absolutn\u011B spolehliv\u00FD ukazatel predikce \u00FA\u010Dinku Herceptinu, nelze vylou\u010Dit, \u017Ee pro n\u011Bkter\u00E9 tyto pacientky by mohla b\u00FDt l\u00E9\u010Dba prosp\u011B\u0161n\u00E1."@cs . "The results of molecular and immunohistochemical testing of HER2/neu status in 2 145 patients with breast cancer are presented. Overexpresion of HER2/neu protein was detected in 591 (27,6%) cases, while 1554 (72,4%) cases were immunohistochemically (IHC) negative. Discordant phenotype IHC negative/amplification positive was found in 16 patients (1,03%). This group of patients could benefit of Herceptin therapy."@en . . . "Molekul\u00E1rn\u00ED testov\u00E1n\u00ED HEr2 u karcinomu prsu jako krit\u00E9rium v\u00FDb\u011Bru nemocn\u00FDch k l\u00E9\u010Db\u011B Herceptinem - jsme optim\u00E1ln\u00ED?"@cs . . "Breast Cancer News" . "V souboru 2145 vy\u0161et\u0159ovan\u00FDch invazivn\u00EDch karcinom\u016F jsme prok\u00E1zali overexpresi HER2 (IHC2-3+) u 591 (27,6%) p\u0159\u00EDpad\u016F; celkem bylo 1554 (72,4%) negativn\u00EDch (IHC0/1+). P\u0159ekvapiv\u00FDm zji\u0161t\u011Bn\u00EDm byla p\u0159\u00EDtomnost amplifikace u 16 (1,03%) IHC negativn\u00EDch karcinom\u016F. Vzhledem k tomu, \u017Ee dodnes neexistuje absolutn\u011B spolehliv\u00FD ukazatel predikce \u00FA\u010Dinku Herceptinu, nelze vylou\u010Dit, \u017Ee pro n\u011Bkter\u00E9 tyto pacientky by mohla b\u00FDt l\u00E9\u010Dba prosp\u011B\u0161n\u00E1." . "Molekul\u00E1rn\u00ED testov\u00E1n\u00ED HEr2 u karcinomu prsu jako krit\u00E9rium v\u00FDb\u011Bru nemocn\u00FDch k l\u00E9\u010Db\u011B Herceptinem - jsme optim\u00E1ln\u00ED?" . . . "CZ - \u010Cesk\u00E1 republika" . "4"^^ . . . . "3"^^ . . "Molecular testing of HER2/neu of patients with breast cancer as a criterium for selection of Herceptin therapy- is our approach optimal?"@en . . "Molecular testing of HER2/neu of patients with breast cancer as a criterium for selection of Herceptin therapy- is our approach optimal?"@en . "Grossmann, Petr" . "2" .